Johnson & Johnson

Rates JNJ as a high-quality defensive dividend growth stock with a 64‑year dividend increase streak but sees shares as slightly overvalued at ~23× earnings versus a fair value multiple of 17, implying modest total returns of roughly 2.1% annually over the next five years and a hold stance. The analysis emphasizes durable recession‑resistant fundamentals, expected 6% EPS growth, and continued dividend safety, with valuation headwinds the main risk to upside.

Highlights JNJ’s 3% dividend increase to an annualized $5.36 per share, extending its streak to 64 consecutive years, alongside a payout ratio drop from 84% to 46% and a current dividend yield near 2%, signaling greater cushion for future raises despite the stock’s strong run. TIKR’s mid‑case model targets a stock price of $335 by late 2030, implying about 27% total return (≈6% annualized), supported by management’s path to $100 billion in 2026 revenue and a pipeline (including ICOTYDE and INLEXZO) viewed as underappreciated by the market.

Reviews Q1 2026 results with revenue up 9.9% to $24.1 billion and adjusted EPS of $2.70, notes strong growth in oncology and MedTech but weaker immunology, and highlights raised 2026 EPS guidance to $11.45–$11.65 plus a 64‑year dividend growth streak. Despite robust fundamentals, the report projects only 4.7% annual total returns through 2031 due to valuation (P/E ~20.3 vs target 17) and potential multiple compression, leading to a hold rating with key risks around biosimilar pressure on Stelara and slower‑than‑expected growth.

Provides a quantified technical and fundamental view, assigning a HOLD action with low confidence and a conservative ATR‑based stop‑loss strategy, noting current price around $234, market cap ~$564 billion, 9.9% revenue growth, and 75.8% institutional ownership with consensus target near $251.08 (+7.2% upside). The report stresses weak technical confluence (0/7 signals), an unfavorable risk/reward profile (~0.48:1), and earnings growth volatility, recommending patience and disciplined risk management rather than aggressive accumulation.

Analyzes Q4 and full‑year 2025 results with revenue up 9.3% in the quarter to $24.6 billion and adjusted EPS rising to $10.79 for the year, citing strong oncology and MedTech performance and a 63‑year dividend growth streak with an “A” Dividend Risk Score. The report forecasts 6% annual EPS growth and 6.0% expected total returns but sees shares trading above the target P/E (19.1 vs 17), so it maintains a hold rating, with valuation, Stelara biosimilar competition, and broader pricing pressures as key risks.

Initiates coverage with a HOLD rating and US$180 target price after a strong quarter in which adjusted EPS of $2.77 beat consensus and revenue grew 5.8% to $23.7 billion, supported by oncology strength and MedTech momentum, prompting raised 2025 guidance for both sales and earnings. However, the note underscores substantial overhangs—ongoing talc litigation involving tens of thousands of claims, Stelara’s looming patent cliff and Medicare price negotiation, intensifying biosimilar competition, and potential tariff/pricing pressures—arguing these headwinds constrain upside despite solid execution.